Yang, Shuang* Dotaz Zobrazit nápovědu
The present study was designed to examine effects of Sinomenine (SM) on glioma cells growth in vivo and in vitro. Cells growth and apoptosis were detected by MTT assay, TUNEL assay and flow cytometric analysis. In the study, SM treatment led to growth inhibition on a series of glioma cell lines, including U87, U373, U251, Hs683 and T98G. SM prevented U87 growth in the nude mice as well. Inhibitory effects of SM on U87 cells proliferation in vitro and in vivo were more effective than that of temozolomide (TMZ), and SM has synergistic effects with TMZ in the glioma therapy. SM induced apoptotic death in U87 cells via activation of caspase-3, caspase-8 and caspase-9, and down-regulation of HIAP, Bcl-2 and survivin. Moreover, we observed SM decreased the expression of phosphorylated STAT3 (p-STAT3) both in vivo and in vitro. Interestingly, using a specific activator of STAT3, we demonstrated overexpression of p-STAT3 impaired, SM mediated growth inhibition and apoptosis induction in the U87 cells. In summary, our results indicate SM induced growth suppression of human glioma cells through inhibiting phosphorylation of STAT3.
- MeSH
- alkaloidy farmakologie terapeutické užití MeSH
- apoptóza genetika imunologie účinky léků MeSH
- astrocyty účinky léků MeSH
- gliom farmakoterapie patologie ultrastruktura MeSH
- kaspasy analýza metabolismus MeSH
- kultivované buňky MeSH
- nádorové buněčné linie imunologie metabolismus účinky léků MeSH
- signální transdukce MeSH
- Sinomenium chemie MeSH
- techniky in vitro MeSH
- transkripční faktor STAT3 antagonisté a inhibitory metabolismus účinky léků MeSH
The occurrence and development of lung cancer is closely related to inflammation. Thus, we conducted the present study to investigate the effects of IL-37 (Interleukin 37), a newly identified anti-inflammatory factor, on non-small cell lung cancer (NSCLC), which accounts for about 85% of all lung cancers. To address the function of IL-37 in NSCLC, we first evaluated IL-37 expression in the human NSCLC tissues; then the IL-37 function was assessed in vitro and in vivo in a xenografted lung tumor model. IL-37 was barely expressed in the NSCLC tissue but highly expressed in the adjacent normal tissue. This expression profile was validated by ELISA (Enzyme-linked immunoassay), western blot and immunohistochemical staining. Recombinant IL-37 could suppress cell migration, invasion and proliferation and promote cell apoptosis in NSCLC cell line A549 and SK-MES-1. IL-37 inhibited the IL-6/STAT3 pathway and also the downstream targets Bcl-2, NEDD9 and Cyclin D1. Overexpressing IL-6 or constitutive active STAT3 eliminated the anti-tumor effects of IL-37. Furthermore, IL-37 expression in vivo could inhibit the cancer development. Our results showed that IL-37 plays an inhibitory role in lung cancer development, possibly through IL-6/STAT3 pathway.
- MeSH
- interleukin-1 genetika metabolismus MeSH
- lidé MeSH
- mediátory zánětu metabolismus MeSH
- nádorová transformace buněk imunologie MeSH
- nemalobuněčný karcinom plic * genetika metabolismus patologie MeSH
- receptory interleukinu-6 antagonisté a inhibitory genetika metabolismus MeSH
- signální transdukce MeSH
- transkripční faktor STAT3 antagonisté a inhibitory genetika metabolismus MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- práce podpořená grantem MeSH
Glycosylation is a topic of intense current interest in the development of biopharmaceuticals because it is related to drug safety and efficacy. This work describes results of an interlaboratory study on the glycosylation of the Primary Sample (PS) of NISTmAb, a monoclonal antibody reference material. Seventy-six laboratories from industry, university, research, government, and hospital sectors in Europe, North America, Asia, and Australia submitted a total of 103 reports on glycan distributions. The principal objective of this study was to report and compare results for the full range of analytical methods presently used in the glycosylation analysis of mAbs. Therefore, participation was unrestricted, with laboratories choosing their own measurement techniques. Protein glycosylation was determined in various ways, including at the level of intact mAb, protein fragments, glycopeptides, or released glycans, using a wide variety of methods for derivatization, separation, identification, and quantification. Consequently, the diversity of results was enormous, with the number of glycan compositions identified by each laboratory ranging from 4 to 48. In total, one hundred sixteen glycan compositions were reported, of which 57 compositions could be assigned consensus abundance values. These consensus medians provide community-derived values for NISTmAb PS. Agreement with the consensus medians did not depend on the specific method or laboratory type. The study provides a view of the current state-of-the-art for biologic glycosylation measurement and suggests a clear need for harmonization of glycosylation analysis methods.
- MeSH
- biofarmacie metody MeSH
- biologické přípravky * MeSH
- glykomika metody MeSH
- glykopeptidy metabolismus MeSH
- glykosylace MeSH
- laboratoře MeSH
- lidé MeSH
- monoklonální protilátky chemie metabolismus MeSH
- polysacharidy metabolismus MeSH
- posttranslační úpravy proteinů MeSH
- proteomika metody MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
In 2008, we published the first set of guidelines for standardizing research in autophagy. Since then, this topic has received increasing attention, and many scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Thus, it is important to formulate on a regular basis updated guidelines for monitoring autophagy in different organisms. Despite numerous reviews, there continues to be confusion regarding acceptable methods to evaluate autophagy, especially in multicellular eukaryotes. Here, we present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes. These guidelines are not meant to be a dogmatic set of rules, because the appropriateness of any assay largely depends on the question being asked and the system being used. Moreover, no individual assay is perfect for every situation, calling for the use of multiple techniques to properly monitor autophagy in each experimental setting. Finally, several core components of the autophagy machinery have been implicated in distinct autophagic processes (canonical and noncanonical autophagy), implying that genetic approaches to block autophagy should rely on targeting two or more autophagy-related genes that ideally participate in distinct steps of the pathway. Along similar lines, because multiple proteins involved in autophagy also regulate other cellular pathways including apoptosis, not all of them can be used as a specific marker for bona fide autophagic responses. Here, we critically discuss current methods of assessing autophagy and the information they can, or cannot, provide. Our ultimate goal is to encourage intellectual and technical innovation in the field.
- MeSH
- autofagie * fyziologie MeSH
- autofagozomy MeSH
- biologické markery MeSH
- biotest normy MeSH
- lidé MeSH
- lyzozomy MeSH
- proteiny spojené s autofagií metabolismus MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
- Research Support, U.S. Gov't, Non-P.H.S. MeSH
- směrnice MeSH
Melanoma Manifesting Hepatic Metastases Shown -- on FDG PET/CT -- Sijuan Zou, MD, Zhaoting Cheng, MD, Shuang MD -- el60 -- Castleman’s Disease of the Kidney Mimicking Renal Cell Carcinoma -- on FDG PET/CT -- Yang Wang, MD, Aisheng Dong, MD, Bo Yang, MD, and Jianping Lu, MD -- e164 -- 18 -- F-FDG PET/CT for Molecular /CT in 2 Cases of Hepatic Pseudolymphoma -- Xinping Zhong, MD, Aisheng Dong, MD, Hui Dong, MD, and Yang
sv.
- MeSH
- nukleární lékařství MeSH
- Publikační typ
- periodika MeSH
- Konspekt
- Lékařské vědy. Lékařství
- NLK Obory
- radiologie, nukleární medicína a zobrazovací metody
Yang (Norway) * 914 -- Section 7D. Yang (China) 1123 -- * poster -- xxiii -- Numerical Models for Calculating the Blood Level of a Drug Yang, J. Sager, D. Daine, R. Corman, B. Bachman, J. Wu and S. Yang and D.J. Yang, D-W. Kim and E.K.
IFIP world conference series on medical informatics Studies in health technology and informatics
sv. ; 27 cm
- MeSH
- informační systémy MeSH
- lékařská informatika MeSH
- lékařství MeSH
- Publikační typ
- kongresy MeSH
- sborníky MeSH
- Konspekt
- Lékařské vědy. Lékařství
- NLK Obory
- lékařská informatika